Cargando…

Impfstoffe gegen COVID-19

The ongoing COVID-19 pandemic represents an emergency situation of devastating proportions. To mitigate its effects, several safe and effective vaccines have been developed in a very short period of time. Currently, four vaccines have been approved by the European Medicines Agency (EMA) and are in u...

Descripción completa

Detalles Bibliográficos
Autores principales: Fathi, Anahita, Mellinghoff, Sibylle C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2021
Materias:
CME
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493542/
https://www.ncbi.nlm.nih.gov/pubmed/34613428
http://dx.doi.org/10.1007/s00108-021-01164-0
_version_ 1784579132639674368
author Fathi, Anahita
Mellinghoff, Sibylle C.
author_facet Fathi, Anahita
Mellinghoff, Sibylle C.
author_sort Fathi, Anahita
collection PubMed
description The ongoing COVID-19 pandemic represents an emergency situation of devastating proportions. To mitigate its effects, several safe and effective vaccines have been developed in a very short period of time. Currently, four vaccines have been approved by the European Medicines Agency (EMA) and are in use in Germany. These include two mRNA vaccines and two vector-based vaccines. They all show very good protective efficacy, especially against severe courses of disease and can significantly contain the pandemic by reducing viral transmission. This article focuses on the development and mechanism of action of the vaccines, their safety and efficacy profile as well as indications for vaccination and current recommendations for the use of vaccines in special groups of people, such as convalescent, immunosuppressed and pregnant patients. Finally, currently open scientific questions are addressed.
format Online
Article
Text
id pubmed-8493542
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Medizin
record_format MEDLINE/PubMed
spelling pubmed-84935422021-10-06 Impfstoffe gegen COVID-19 Fathi, Anahita Mellinghoff, Sibylle C. Internist (Berl) CME The ongoing COVID-19 pandemic represents an emergency situation of devastating proportions. To mitigate its effects, several safe and effective vaccines have been developed in a very short period of time. Currently, four vaccines have been approved by the European Medicines Agency (EMA) and are in use in Germany. These include two mRNA vaccines and two vector-based vaccines. They all show very good protective efficacy, especially against severe courses of disease and can significantly contain the pandemic by reducing viral transmission. This article focuses on the development and mechanism of action of the vaccines, their safety and efficacy profile as well as indications for vaccination and current recommendations for the use of vaccines in special groups of people, such as convalescent, immunosuppressed and pregnant patients. Finally, currently open scientific questions are addressed. Springer Medizin 2021-10-06 2021 /pmc/articles/PMC8493542/ /pubmed/34613428 http://dx.doi.org/10.1007/s00108-021-01164-0 Text en © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle CME
Fathi, Anahita
Mellinghoff, Sibylle C.
Impfstoffe gegen COVID-19
title Impfstoffe gegen COVID-19
title_full Impfstoffe gegen COVID-19
title_fullStr Impfstoffe gegen COVID-19
title_full_unstemmed Impfstoffe gegen COVID-19
title_short Impfstoffe gegen COVID-19
title_sort impfstoffe gegen covid-19
topic CME
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493542/
https://www.ncbi.nlm.nih.gov/pubmed/34613428
http://dx.doi.org/10.1007/s00108-021-01164-0
work_keys_str_mv AT fathianahita impfstoffegegencovid19
AT mellinghoffsibyllec impfstoffegegencovid19